UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): August 8, 2017
THERAVANCE BIOPHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Cayman Islands |
|
001-36033 |
|
98-1226628 |
PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman, Cayman Islands KY1-1104
(650) 808-6000
(Addresses, including zip code, and telephone number, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition.
On August 8, 2017, Theravance Biopharma, Inc. issued a press release and is holding a conference call regarding its financial results for the quarter ended June 30, 2017 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit 99.2 to this Current Report.
The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated August 8, 2017
99.2 Materials Accompanying the Call
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
THERAVANCE BIOPHARMA, INC. | |
|
|
|
|
|
|
|
|
|
Date: August 8, 2017 |
By: |
/s/ Renee D. Gala |
|
|
|
Renee D. Gala |
|
|
|
Senior Vice President and Chief Financial Officer |
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release dated August 8, 2017 |
|
99.2 |
|
Materials Accompanying the Call |
Exhibit 99.1
Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update
Meaningful Clinical Readouts Underpin Progress in Key Programs
Additional Milestones Anticipated in Remainder of 2017 and 2018
DUBLIN, IRELAND — AUGUST 8, 2017 — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today reported financial results for the second quarter ended June 30, 2017. Revenue for the second quarter of 2017 was $3.5 million. The second quarter operating loss was $65.1 million, or $54.7 million excluding non-cash share-based compensation expense of $10.4 million. Cash, cash equivalents, and marketable securities totaled $498.3 million as of June 30, 2017.
Rick E Winningham, Chairman and Chief Executive Officer, commented: “We are incredibly pleased with our progress to date in 2017, which includes the delivery of meaningful clinical data across a number of our key pipeline programs. We are in an unprecedented period at Theravance Biopharma, driven by the depth and breadth of our portfolio, the talents and insights of our team, and the overall productivity of our R&D engine.”
Recent Pipeline Updates
· Positive results announced from a 12-month Phase 3 safety study of revefenacin (TD-4208), the Company’s once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), partnered with Mylan.
· Positive results announced in the 5 mg treatment arm of velusetrag (5-HT4 agonist; TD-5108) from a Phase 2b study in patients with gastroparesis.
· Early evidence of localized target engagement announced from first cohort of Phase 1b study of TD-1473 (intestinally restricted pan-Janus kinase (JAK) inhibitor) in patients with ulcerative colitis.
Expected Upcoming Milestones and Events
· Revefenacin (TD-4208): NDA filing anticipated in 4Q 2017; completion of the Phase 3b PIFR study in the first quarter of 2018, designed to support commercialization; potential regulatory approval in the US for COPD in 2018.
· Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol)1: Results from the Phase 3 IMPACT study in 2017; potential regulatory approval in the US and EU for COPD in late 2017; Phase 3 CAPTAIN study completion in asthma patients and potential supplementary regulatory submissions for asthma in 2018.
· VIBATIV: Televancin Observational Use Registry (TOURTM) data to be published throughout remainder of 2017; data from the Phase 3 registrational bacteremia study in 2018 or 2019.
· TD-1473: Data from the remaining cohorts of the Phase 1b study in patients with ulcerative colitis in 2018; targeting initiation of induction and maintenance study in 2018.
· TD-9855 (NSRI): Data from the Phase 2a study in patients with nOH in first half of 2018.
Notes:
1 As reported by Glaxo Group Limited or one of its affiliates (GSK)
Second Quarter Financial Results
Revenue
Revenue for the second quarter of 2017 was $3.5 million, primarily related to U.S. net product sales of VIBATIV®. This represents a decrease of $2.0 million from the same period in 2016, reflecting the impact of generic competitive products in the outpatient market.
Research and Development (R&D) Expenses
R&D expenses for the second quarter of 2017 were $42.9 million representing an increase of $10.9 million compared to the same period in 2016. The increase is driven by costs associated with the progression of our key programs as well as increased employee-related costs. Second quarter R&D expenses include non-cash share-based compensation expense of $4.9 million.
Selling, General and Administrative (SG&A) Expenses
SG&A expenses for the second quarter of 2017 were $24.3 million, representing an increase of $4.1 million compared to the same period in 2016. The increase is due to employee-related costs, external expenses related to G&A, and share-based compensation, partially offset by a reduction in external expenses related to commercialization activities. Second quarter SG&A expenses include non-cash share-based compensation expense of $5.5 million.
Cash, Cash Equivalents and Marketable Securities
Cash, cash equivalents and marketable securities, excluding restricted cash, totaled $498.3 million as of June 30, 2017.
2017 Financial Guidance
The Company is revising its guidance for operating loss excluding non-cash share-based compensation for the full-year of 2017 to a range of $205.0 million to $215.0 million. The increase in guidance is primarily driven by the Company’s decision to accelerate spending associated with the next phase of development in the JAK inhibitor program. The actual amount could be above or below this forecast as a result of a variety of factors impacting our business, including the timing and cost of clinical and non-clinical studies associated with our key programs and net product sales of VIBATIV®.
Conference Call Today at 5:00 pm ET
Theravance Biopharma will hold a conference call today at 5:00 pm ET. To participate in the live call by telephone, please dial (855) 296-9648 from the U.S., or (920) 663-6266 for international callers, using the confirmation code 41381031. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma’s website at www.theravance.com, under
the Investor Relations section, Presentations and Events. Please go to the website 15 minutes prior to the start of the call to register, download, and install any necessary audio software.
A replay of the conference call will be available on Theravance Biopharma’s website for 30 days through September 7, 2017. An audio replay will also be available through 8:00 pm ET on August 15, 2017 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and then entering confirmation code 41381031.
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma.
For more information, please visit www.theravance.com.
THERAVANCE®, the Cross/Star logo, and VIBATIV® are registered trademarks of the Theravance Biopharma group of companies. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
This press release contains and the conference call will contain certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company’s strategies, plans and objectives, the Company’s regulatory strategies and timing of clinical studies (including the data therefrom), the potential benefits and mechanisms of action of the Company’s product and product candidates, the Company’s expectations for product candidates through development, potential regulatory approval and commercialization (including
their potential as components of combination therapies), product sales and the Company’s expectations for its 2017 operating loss, excluding share-based compensation. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of the press release and the conference call and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: delays or difficulties in commencing, enrolling or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company’s product candidates are unsafe or ineffective (including when our product candidates are studied in combination with other compounds), the feasibility of undertaking future clinical trials for our product candidates based on FDA policies and feedback, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products, risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure, and risks of developing an institutional customer mix for VIBATIV® (telavancin) that meet the Company’s plan for the product. Other risks affecting Theravance Biopharma are described under the heading “Risk Factors” contained in Theravance Biopharma’s Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 9, 2017 and Theravance Biopharma’s other filings with the SEC. In addition to the risks described above and in Theravance Biopharma’s filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
Contact Information:
Alexander Dobbin
Head of Investor Relations
650-808-4045
investor.relations@theravance.com
THERAVANCE BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
| ||||||||
|
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
|
|
(Unaudited) |
|
(Unaudited) |
| ||||||||
|
Revenue: |
|
|
|
|
|
|
|
|
| ||||
|
Product sales |
|
$ |
3,474 |
|
$ |
5,359 |
|
$ |
6,524 |
|
$ |
8,670 |
|
|
Revenue from collaborative arrangements |
|
35 |
|
112 |
|
72 |
|
15,211 |
| ||||
|
Total revenue |
|
3,509 |
|
5,471 |
|
6,596 |
|
23,881 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Costs and expenses: |
|
|
|
|
|
|
|
|
| ||||
|
Cost of goods sold |
|
1,364 |
|
638 |
|
1,929 |
|
1,416 |
| ||||
|
Research and development (1) |
|
42,927 |
|
32,069 |
|
83,492 |
|
67,748 |
| ||||
|
Selling, general and administrative (1) |
|
24,339 |
|
20,261 |
|
45,125 |
|
43,857 |
| ||||
|
Total costs and expenses |
|
68,630 |
|
52,968 |
|
130,546 |
|
113,021 |
| ||||
|
Loss from operations |
|
(65,121 |
) |
(47,497 |
) |
(123,950 |
) |
(89,140 |
) | ||||
|
Interest expense |
|
(2,137 |
) |
— |
|
(4,274 |
) |
— |
| ||||
|
Interest and other income (loss), net |
|
1,425 |
|
308 |
|
2,455 |
|
495 |
| ||||
|
Loss before income taxes |
|
(65,833 |
) |
(47,189 |
) |
(125,769 |
) |
(88,645 |
) | ||||
|
Provision for income taxes |
|
454 |
|
36 |
|
5,837 |
|
730 |
| ||||
|
Net loss |
|
$ |
(66,287 |
) |
$ |
(47,225 |
) |
$ |
(131,606 |
) |
$ |
(89,375 |
) |
|
|
|
|
|
|
|
|
|
|
| ||||
|
Net loss per share: |
|
|
|
|
|
|
|
|
| ||||
|
Basic and diluted net loss per share |
|
$ |
(1.27 |
) |
$ |
(1.06 |
) |
$ |
(2.53 |
) |
$ |
(2.16 |
) |
|
Shares used to compute basic and diluted net loss per share |
|
52,255 |
|
44,407 |
|
51,938 |
|
41,366 |
| ||||
(1) Amounts include share-based compensation expense as follows:
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
| ||||||||
|
(In thousands) |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
| ||||
|
Research and development |
|
$ |
4,917 |
|
$ |
4,959 |
|
$ |
10,018 |
|
$ |
10,119 |
|
|
Selling, general and administrative |
|
5,481 |
|
4,945 |
|
10,649 |
|
11,115 |
| ||||
|
Total share-based compensation expense |
|
$ |
10,398 |
|
$ |
9,904 |
|
$ |
20,667 |
|
$ |
21,234 |
|
THERAVANCE BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
|
|
|
June 30, |
|
December 31, |
| ||
|
|
|
2017 |
|
2016 |
| ||
|
|
|
(Unaudited) |
|
(1) |
| ||
|
Assets |
|
|
|
|
| ||
|
Current assets: |
|
|
|
|
| ||
|
Cash and cash equivalents and short-term marketable securities |
|
$ |
361,820 |
|
$ |
501,096 |
|
|
Receivables from collaborative arrangements |
|
5,318 |
|
9,076 |
| ||
|
Prepaid taxes |
|
242 |
|
3,060 |
| ||
|
Inventories |
|
12,126 |
|
12,220 |
| ||
|
Other prepaid and current assets |
|
5,376 |
|
3,051 |
| ||
|
Property and equipment, net |
|
8,679 |
|
8,460 |
| ||
|
Long-term marketable securities |
|
136,445 |
|
91,565 |
| ||
|
Restricted cash |
|
833 |
|
833 |
| ||
|
Other assets |
|
13,047 |
|
9,893 |
| ||
|
Total assets |
|
$ |
543,886 |
|
$ |
639,254 |
|
|
|
|
|
|
|
| ||
|
Liabilities and Shareholders’ Equity |
|
|
|
|
| ||
|
Current liabilities |
|
57,103 |
|
49,268 |
| ||
|
Long-term liabilities |
|
245,656 |
|
239,755 |
| ||
|
Shareholders’ equity |
|
241,127 |
|
350,231 |
| ||
|
Total liabilities and shareholders’ equity |
|
$ |
543,886 |
|
$ |
639,254 |
|
(1) The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
Exhibit 99.2
Q2 2017 Financial Results and Business Update August 8, 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH)
Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to differ materially from the forward-looking statements or projections. Examples of forward-looking statements in this presentation include statements relating to the company’s business plans and objectives, including financial and operating results, potential partnering transactions and sales targets, the company’s regulatory strategies and timing and results of clinical studies, the potential benefits and mechanisms of action of the company’s product and product candidates (including their potential as components of combination therapies). The company’s forward-looking statements are based on the estimates and assumptions of management as of the date of this presentation and are subject to risks and uncertainties that may cause the actual results to be materially different than those projected, such as risks related to delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective (including when our product candidates are studied in combination with other compounds), delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with third parties to discover, develop and commercialize products, risks associated with establishing and maintaining sales, marketing and distribution capabilities. Other risks affecting the company are described under the heading “Risk Factors” and elsewhere in the company’s Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 9, 2017, and other periodic reports filed with the SEC.
Upcoming Milestones Program Milestone Target TD-1439 (NEP inhibitor) Phase 1a SAD/MAD results in healthy volunteers Completed Revefenacin (TD-4208) Phase 3 long-term safety results in COPD patients Completed Velusetrag (TD-5108) Phase 2b results in Gastroparesis patients Completed TD-1473 (JAK inhibitor) Phase 1b results in UC patients, Cohort 1 Completed Revefenacin (TD-4208) NDA submission in US* 2017 VIBATIV® (telavancin) Patient registry study data (TOURTM) 2017 Closed Triple (FF/UMEC/VI)1 Phase 3 IMPACT study completion 2017 Closed Triple (FF/UMEC/VI)1 Potential regulatory approval in US and EU for COPD* 2017 TD-1473 (JAK inhibitor) Phase 1b results in UC patients, Cohorts 2 and 3 2018 TD-9855 (NSRI) Phase 2a results in nOH patients 2018 Revefenacin (TD-4208) Phase 3b study results in COPD patients with low PIFR2 2018 Revefenacin (TD-4208) Potential regulatory approval in US for COPD* 2018 VIBATIV® (telavancin) Phase 3 study data in Bacteremia patients 2018 / 2019 Closed Triple (FF/UMEC/VI)1 Phase 3 study completion in Asthma patients 2018 Closed Triple (FF/UMEC/VI)1 Supplementary regulatory submissions for Asthma* 2018 Multiple Opportunities for Value Creation in Near-term 1 Economic interests. Regulatory and clinical milestones as reported by GlaxoSmithKline 2 Peak inspiratory flow rate * Submissions, filings, and approvals are subject to preclinical and clinical data and regulatory interactions
JAK Inhibitor Program Oral intestinally-restricted pan-Janus kinase (JAK) inhibitors for ulcerative colitis and other inflammatory intestinal diseases
Phase 1b designed to evaluate safety, tolerability, PK and PD of TD-1473 in moderately-to-severely active ulcerative colitis patients over 28 days Secondary/exploratory objectives to demonstrate biologic effect through biomarker analysis and clinical, endoscopic and histologic assessments TD-1473: Phase 1b Study Progressing in Ulcerative Colitis Patients Randomized Rx Dosing daily for 28 days (Cohort 1 complete; Cohorts 2 and 3 will overlap) TD-1473 20 mg: placebo QD (10:3) TD-1473 80 mg: placebo QD (10:3) TD-1473 270 mg: placebo QD (10:3) Encouraging data from first cohort support target product profile
Evidence of Localized Target Engagement and Minimal Systemic Exposure from Cohort 1 of TD-1473 Phase 1b TD-1473 to advance into induction and maintenance study in 2018 Minimal Systemic Exposure; No Evidence of Systemic Immunosuppression Minimal levels of drug in plasma, consistent with SAD/MAD in healthy volunteers No evidence of infections, including no occurrences of zoster reactivation Early Signs of Biological Target Engagement 7 of 10 patients on TD-1473 experienced > 1-point reduction in Mayo rectal bleeding subscore, compared to 1 of 3 patients on placebo 3 of 10 patients on TD-1473 experienced > 1-point reduction in Mayo endoscopic subscore, compared to zero patients in placebo group 2 of 10 patients on TD-1473 showed evidence of mucosal healing1, compared to zero placebo patients 2 of 10 patients on TD-1473 achieved clinical response by total Mayo Score, compared to zero patients on placebo 4 of 10 patients receiving TD-1473 achieved clinical response by partial Mayo score, compared to 1 of 3 patients receiving placebo Reductions in levels of CRP, FC and pSTAT1 in patients on TD-1473 Safety Data No moderate or serious adverse events (AEs) related to TD-1473 AEs reported with TD-1473 were mild in severity; none led to discontinuation 1 Mucosal healing based on modified Mayo endoscopy score. CRP = C-Reactive Protein; FC = Fecal Calprotectin; pSTAT1 = phosphorylated signal transducer and activator of transcription1
Velusetrag (TD-5108) Highly selective 5-HT4 agonist for gastroparesis
Phase 2b Results Provide POC in Symptom Effect First Clinical Evaluation of Effect of Velusetrag on Symptoms of Gastroparesis Scintigraphy Retention % after 28 Days Dosing LS Mean Change from Baseline GCSI Total Score Weeks Hours *Nominal p value for all doses < 0.001 versus placebo *Nominal p-value < 0.05 on difference from placebo Treatment Period Follow-up 5 mg demonstrated statistically significant improvements in gastroparesis symptoms compared to placebo Inverse dose response observed; 15 and 30 mg dose groups not statistically significant All doses significantly improve gastric emptying at 4 hours Generally well tolerated, AEs and SAEs comparable at 5 mg and placebo, SAEs low across all treatment groups Statistical significance at 5 mg provides confidence in robust treatment effect
Developing Propriety PRO to Validate for Phase 3 Gastroparesis Rating Scale (GRS) Designed in Alignment with FDA Guidance Week 4 GRS Subscale Score LS Mean Change from Baseline GRS Total Score Weeks *Nominal p-value < 0.05 on difference from placebo Treatment Period Follow-up GRS evaluates 7 symptom domains, including upper abdominal pain Enduring effect of 5 mg; symptom improvements at weeks 1 – 4 and week 12 Consistent improvement across all individual GRS subscale scores Preparing to meet with regulators to discuss validation of the GRS PRO and next phase of development for velusetrag
Revefenacin (TD-4208) Nebulized Long-Acting Muscarinic Antagonist (LAMA) for COPD
* P < 0.0001 versus placebo ** P <0.001 versus placebo * ** * * * ** Revefenacin: Phase 3 Registrational Program Complete, with NDA Filing Planned in Late 2017 Primary endpoint achieved for both doses in both replicate efficacy studies Robust and sustained improvements in FEV1 Effective as monotherapy and as add-on to LABA or LABA/ICS Generally well tolerated Generally well tolerated in 12-month safety study No new safety issues identified Rates of adverse events low and comparable to standard of treatment FEV1 = forced expiratory volume in one second
Upcoming Milestones Program Milestone Target TD-1439 (NEP inhibitor) Phase 1a SAD/MAD results in healthy volunteers Completed Revefenacin (TD-4208) Phase 3 long-term safety results in COPD patients Completed Velusetrag (TD-5108) Phase 2b results in Gastroparesis patients Completed TD-1473 (JAK inhibitor) Phase 1b results in UC patients, Cohort 1 Completed Revefenacin (TD-4208) NDA submission in US* 2017 VIBATIV® (telavancin) Patient registry study data (TOURTM) 2017 Closed Triple (FF/UMEC/VI)1 Phase 3 IMPACT study completion 2017 Closed Triple (FF/UMEC/VI)1 Potential regulatory approval in US and EU for COPD* 2017 TD-1473 (JAK inhibitor) Phase 1b results in UC patients, Cohorts 2 and 3 2018 TD-9855 (NSRI) Phase 2a results in nOH patients 2018 Revefenacin (TD-4208) Phase 3b study results in COPD patients with low PIFR2 2018 Revefenacin (TD-4208) Potential regulatory approval in US for COPD* 2018 VIBATIV® (telavancin) Phase 3 study data in Bacteremia patients 2018 / 2019 Closed Triple (FF/UMEC/VI)1 Phase 3 study completion in Asthma patients 2018 Closed Triple (FF/UMEC/VI)1 Supplementary regulatory submissions for Asthma* 2018 Multiple Opportunities for Value Creation in Near-term 1 Economic interests. Regulatory and clinical milestones as reported by GlaxoSmithKline 2 Peak inspiratory flow rate * Submissions, filings, and approvals are subject to preclinical and clinical data and regulatory interactions
Q&A
